DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



[Effects of 2% ibopamine eye drops on computerized visual field results]

Author(s): Pigini MA, Avila MP, Magacho L

Affiliation(s): Universidade Federal de Goias, Goiania, GO, Brasil. maraagi@hotmail.com

Publication date & source: 2009-05, Arq Bras Oftalmol., 72(3):365-9.

Publication type: English Abstract

PURPOSE: To evaluate the influence of 2% ibopamine eye drops on the results of computerized visual field exams. METHODS: Normal volunteers from CEROF-UFG were selected, with no variance in the ophthalmologic examination that could affect the visual field test. The volunteers underwent computerized visual field test before and after dilation with 2% ibopamine eye drop or cyclopentolate, with a minimum interval of three days between them and in a random order. Global indices and number of altered points were compared between the groups. RESULTS: Thirty eyes of 30 normal individuals were selected. There was no statistically significant difference on Mean Deviation (MD) before and after dilation with ibopamine (MD: -1.05 +/- 0.26 dB vs. -1.47 +/- 0.20 dB, P=0.08). However, after cycloplegia (MD: -3.19 +/- 0.29 dB), there was a significant difference on MD (P<0.001 for both ibopamine and pre-dilation). No significant difference was detected in the Pattern Standard Deviation when comparing ibopamine with pre-dilation and cycloplegia values, but it was statistically significant comparing pre-dilation to cycloplegia (P=0.04). The number of altered points in the Pattern Deviation graphic were not significant comparing all pairs. There was a statistically significant difference in the number of altered points in the total deviation graphic before dilation and after cycloplegia (n: 8.86 +/- 1.51 vs. 25.72 +/- 2.96 points, P<0.001), and comparing cycloplegia with ibopamine (ibopamine: 9.75 +/- 1.85 points, P<0.001). CONCLUSION: Ibopamine 2% eye drops seem to not modify the results of visual field tests in normal individuals.

Page last updated: 2009-10-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017